Sam Slutsky, an analyst from LifeSci Capital, has initiated a new Buy rating on Palvella Therapeutics (PVLA).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky’s rating is based on Palvella Therapeutics’ innovative approach in developing treatments for rare genetic dermatological diseases using its proprietary QTORIN platform. The platform’s ability to deliver high molecular weight compounds topically with minimal systemic absorption is a significant advantage, particularly for conditions like microcystic lymphatic malformations (MLMs) and cutaneous venous malformations (CVMs), which currently lack FDA-approved therapies.
Palvella’s lead asset, QTORIN 3.9% rapamycin, has shown promising Phase 2 results in MLMs, and there is a strong mechanistic rationale for its efficacy due to the role of mTOR inhibition. The company’s future prospects are further bolstered by expected trial readouts and plans to expand indications, which could drive significant revenue growth. Slutsky’s confidence is reflected in the projected 2037 sales figures and the potential for additional catalysts and revenue opportunities, justifying the Buy rating.
In another report released on July 22, Scotiabank also maintained a Buy rating on the stock with a $50.00 price target.